Categories
Change Password!
Reset Password!
Ruxolitinib cream brings relief for mild-to-moderate atopic dermatitis by providing itch relief, lesion improvement, and flare control, satisfying patients and doctors alike.
Recent findings by Lawrence F. Eichenfield et al. exposed the remarkable efficacy of Ruxolitinib cream in managing atopic dermatitis (AD) among adult patients in real-world clinical settings. Whether administered alone or in combination with other regimens, Ruxolitinib cream showcased consistent results, offering hope across the spectrum of the disease.
Ruxolitinib cream was approved by the US FDA in 2021 for atopic AD in patients aged 12 years and older. However, there are limited studies about real-world evidence of its effectiveness and physician satisfaction with its use. Therefore, this study was performed to describe disease control among adults with AD prescribed Ruxolitinib cream and related healthcare physician satisfaction. The study researchers delved into the AD Disease Specific Programme from August 2022 to March 2023. Drawing from physician-reported data of 1360 AD patients, 149 had received Ruxolitinib cream (in combination or as a single therapy) for at least one month, including 59 patients receiving monotherapy.
Initially, 84.6% of patients initially classified with moderate AD (Investigator’s Global Assessment, IGA=3) to a mere 21.5% post-treatment, with nearly half boasting clear or nearly clear skin. A vast majority (81.2%) reported no current flare-ups, with an overwhelming 87.3% of physicians expressing satisfaction with the achieved disease control and consistent outcomes among those who received only Ruxolitinib cream.
The key motivations for the prescription of Ruxolitinib cream included easing itchiness, reducing redness and thickness of the lesions, disease control and managing flares, described the researchers.
Dermatology and Therapy
Satisfaction with Control of Mild to Moderate Atopic Dermatitis with Ruxolitinib Cream: US Physician and Patient Perspectives
Lawrence F. Eichenfield et al.
Comments (0)